NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.10.18	Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update (Businesswire)
24.10.18	Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors (Businesswire)
23.10.18	Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma (Businesswire)
22.10.18	Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields (Businesswire)
18.10.18	Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune® (Businesswire)
04.10.18	Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018 (Businesswire)
01.10.18	Novocure to Report Third Quarter 2018 Financial Results (Businesswire)
25.09.18	Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer (Businesswire)
22.09.18	Week Ahead In Pharmaceuticals: 10 Stocks To Watch (CKPT, SNDX, ADMP...) (RTTNews)
12.09.18	Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China (Businesswire)
15.08.18	Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer (Businesswire)
03.08.18	Novocure to Present at Two Upcoming Investor Conferences (Businesswire)
02.08.18	Novocure Announces Addition to Its Board of Directors (Businesswire)
26.07.18	Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update (Businesswire)
19.07.18	Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting (Businesswire)
17.07.18	Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society (Businesswire)
02.07.18	Novocure Appoints Pritesh Shah as Chief Commercial Officer (Businesswire)
02.07.18	Novocure to Report Second Quarter 2018 Financial Results (Businesswire)
04.06.18	Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018 (Businesswire)
31.05.18	Novocure Announces Changes to Its Board of Directors (Businesswire)
26.04.18	Novocure Reports First Quarter 2018 Financial Results and Provides Company Update (Businesswire)
18.04.18	GWPH Faces FDA Panel Today, NVCR Reports STELLAR Data, 1st XLH Drug Cleared (RTTNews)
17.04.18	Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma (Businesswire)
13.04.18	Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting (Businesswire)
03.04.18	Novocure to Report First Quarter 2018 Financial Results (Businesswire)
20.03.18	NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma (Businesswire)
15.03.18	Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 (Businesswire)
22.02.18	Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update (Businesswire)
07.02.18	Novocure Secures New $150 Million Non-Dilutive Term Loan Financing (Businesswire)
09.01.18	Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue (Businesswire)
20.12.17	Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference (Businesswire)
19.12.17	JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma (Businesswire)
18.12.17	Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer (Businesswire)
06.12.17	RVNC's All Smiles, NVCR Catches Eyes, ACRS Waiting For Xmas Gift, KIDS Growing (RTTNews)
01.12.17	Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma (Businesswire)
22.11.17	Novocure to Present at Two Upcoming Investor Conferences in December (Businesswire)
13.11.17	Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology (Businesswire)
09.11.17	Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology (Businesswire)
08.11.17	Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology (Businesswire)
06.11.17	Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology (Businesswire)
17.10.17	HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL (RTTNews)
16.10.17	Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer (Businesswire)
02.10.17	Novocure to Report Third Quarter 2017 Financial Results (Businesswire)
25.09.17	Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients (Businesswire)
22.09.17	Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting (Businesswire)
08.09.17	Der Gemeinsame Bundesausschuss beschliesst die Einleitung des Beratungsverfahrens für eine Erprobungs-Richtlinie zum Einsatz von Optune® in der Behandlung des neu diagnostizierten Glioblastoms (Businesswire)
08.09.17	Novocure kündigt Datenpräsentationen für den ESMO-Kongress 2017 an (Businesswire)
06.09.17	Novocure Announces Data Presentations at the ESMO 2017 Congress (Businesswire)
05.09.17	German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma (Businesswire)
24.08.17	Novocure to Present at Two Upcoming Investor Conferences in September (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	133.45	4.42 %	K V
Swiss Life Hldg	693.40	0.90 %	K V
Zurich Insur Gr	552.00	0.77 %	K V
Kuehne+Nagel Int	206.20	0.59 %	K V
Sonova Hldg	294.00	0.58 %	K V
Sika	227.50	-1.34 %	K V
Geberit	537.80	-1.68 %	K V
Part Grp Hldg	1’262.00	-1.75 %	K V
Alcon	75.10	-1.91 %	K V
Lonza Grp	535.80	-2.26 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten